✦ LIBER ✦

RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer

✍ Scribed by E. Ratner; F. Keane; H. Yu; D. Zelterman; T. Rutherford; A. Santin; P. Schwartz; F. Slack; D. Levine; J. Weidhaas

Book ID: 113962733
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 206 KB
Volume: 120
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2010.12.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Retraction to “A 3′ UTR KRAS variant as

Retraction to “A 3′ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer” [Gynecol. Oncol. 120 (2011) S3]

✍ E. Ratner; F. Keane; H. Yu; D. Zelterman; T. Rutherford; A. Santin; P. Schwartz; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 83 KB

A KRAS variant is a biomarker of poor ou

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer

✍ Ratner, E S; Keane, F K; Lindner, R; Tassi, R A; Paranjape, T; Glasgow, M; Nallu 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 758 KB

Identification of a genetic variant asso

Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy

✍ Georgia Chenevix-Trench; Yi Lu; Sharon Johnatty; Eric Gamazon; Jonathan Beesley; 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 81 KB

SERPINB3 in the chicken model of ovarian

SERPINB3 in the chicken model of ovarian cancer: A novel biomarker for predicting platinum resistance and survival in patients with epithelial ovarian cancer

✍ H. Kim; G. Song; W. Lim; Y. Kim; M. Kim; M. Kim; N. Park; F. Bazer; J. Han; Y. S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 411 KB

PIK3CA exon 20 mutations as a potential

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

✍ Mao, C.; Yang, Z. Y.; Hu, X. F.; Chen, Q.; Tang, J. L. 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 552 KB

Loss of trimethylation at lysine 27 of h

Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers

✍ Yongkun Wei; Weiya Xia; Zhihong Zhang; Jinsong Liu; Huamin Wang; Nazmi V. Adsay; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

## Abstract Methylation of lysine 27 on histone H3 (H3K27) by the EZH2 complex is an epigenetic mark that mediates gene silencing. EZH2 is overexpressed in many cancers and correlates with poor prognosis in both breast and prostate cancers. However, the status of H3K27 methylation and its clinical